Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator

Ivacaftor (VX-770) was the first cystic fibrosis transmembrane conductance regulator (CFTR) modulatory drug approved for the treatment of patients with cystic fibrosis. Electron cryomicroscopy (cryo-EM) studies of detergent-solubilized CFTR indicated that VX-770 bound to a site at the interface betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Laselva, Onofrio, Qureshi, Zafar, Zeng, Zhi-Wei, Petrotchenko, Evgeniy V., Ramjeesingh, Mohabir, Hamilton, C. Michael, Huan, Ling-Jun, Borchers, Christoph H., Pomès, Régis, Young, Robert, Bear, Christine E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184517/
https://www.ncbi.nlm.nih.gov/pubmed/34142049
http://dx.doi.org/10.1016/j.isci.2021.102542

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184517/
https://www.ncbi.nlm.nih.gov/pubmed/34142049
http://dx.doi.org/10.1016/j.isci.2021.102542

Ejemplares similares